BioPharma Dive July 1, 2021
A five-year alliance with ElevateBio is designed to get around a bottleneck that has held back the institution’s gene therapy work.
ElevateBio, a privately held biotech with hefty financial backing, has formed a five-year alliance with Boston Children’s Hospital that could lead to the creation of several new gene and cell therapy startups.
The agreement gives Boston Children’s researchers access to a suite of scientific tools and ElevateBio’s 140,000-square-foot manufacturing facility in Waltham, Massachusetts. That assistance should help Boston Children’s speed development of gene therapy research that the institution has struggled to progress into clinical testing.
“We’re not a drug company,” said David Williams, chief of Boston Children’s hematology and oncology division, in an interview. “We’ve looked for ways...